Acute treatment with fluvoxamine elevates rat brain serotonin synthesis in some terminal regions: An autoradiographic study

Mück‐Šeler, Dorotea; Pivac, Nela; Dikšić, Mirko

doi:10.1016/j.nucmedbio.2012.04.001

Cited by 13 publications

(15 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Muck-Seler et al 36 reported that fluvoxamine administration decreased 5-HT synthesis rates in serotonergic cell bodies in the raphe magnus, with a trend toward decrease in the dorsal and median raphe nuclei. On the other hand, 5-HT synthesis rates were increased in the hippocampus, substantia nigra, and hypothalamus, and remained unchanged in the caudate-putamen and nucleus accumbens.…”

Section: Discussionmentioning

confidence: 99%

Fluvoxamine alters the activity of energy metabolism enzymes in the brain

Ferreira

Cardoso

Jeremias

et al. 2014

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: Several studies support the hypothesis that metabolism impairment is involved in the pathophysiology of depression and that some antidepressants act by modulating brain energy metabolism. Thus, we evaluated the activity of Krebs cycle enzymes, the mitochondrial respiratory chain, and creatine kinase in the brain of rats subjected to prolonged administration of fluvoxamine. Methods: Wistar rats received daily administration of fluvoxamine in saline (10, 30, and 60 mg/kg) for 14 days. Twelve hours after the last administration, rats were killed by decapitation and the prefrontal cortex, cerebral cortex, hippocampus, striatum, and cerebellum were rapidly isolated. Results: The activities of citrate synthase, malate dehydrogenase, and complexes I, II-III, and IV were decreased after prolonged administration of fluvoxamine in rats. However, the activities of complex II, succinate dehydrogenase, and creatine kinase were increased. Conclusions: Alterations in activity of energy metabolism enzymes were observed in most brain areas analyzed. Thus, we suggest that the decrease in citrate synthase, malate dehydrogenase, and complexes I, II-III, and IV can be related to adverse effects of pharmacotherapy, but long-term molecular adaptations cannot be ruled out. In addition, we demonstrated that these changes varied according to brain structure or biochemical analysis and were not dose-dependent.

show abstract

Section: Discussionmentioning

confidence: 99%

Fluvoxamine alters the activity of energy metabolism enzymes in the brain

Ferreira

Cardoso

Jeremias

et al. 2014

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Prior to treatment, the animals were weighed, and the volume of FM to be injected (1 ml/250 g of body weight) was calculated accordingly. FM was freshly prepared by dissolving in saline after which it was injected (25 mg/kg, i.p) (Gerstenberg et al, 2003; Muck‐seler et al, 2012). Animals receiving FM prior to the lesion (NSPr‐F and MSPr‐F) received the drug for 30 days, and those receiving it post‐lesion (NSPt‐F and MSPt‐F) received it for 15 days.…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…The antidepressant, Fluvoxamine maleate (FM) is a selective serotonin reuptake inhibitor (SSRI) widely used in the treatment of depression and anxiety disorders (Muck‐seler et al, 2012). FM increases serotoninergic neurotransmission via potent and selective inhibition of serotonin (5‐HT) reuptake into presynaptic neurons (Muck‐seler et al, 2012). Among 5‐HT system receptors, the 5‐HT 1A receptors have been shown to be involved in the enhancement of FM‐induced increases in prefrontal DA release and play a key role in the mechanism of action of the drug (Hasebe et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐parkinsonian effects of fluvoxamine maleate in maternally separated rats

Dallé¹,

Daniels²,

Mabandla³

2016

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

Exposure to early life stress has been shown to result in anxiety-like symptoms and exacerbates degeneration of dopaminergic neurons in a rat model of Parkinson's disease (PD). First line treatment for anxiety disorders includes the use of Fluvoxamine maleate (FM). In this study, we investigated whether treating anxiety-like symptoms with FM has an effect in alleviating the neurotoxic effects of 6-OHDA in a parkinsonian rat model. Early maternal separation was used to create a rat model that depicts anxiety-like symptoms. Maternally separated adult Sprague-Dawley rats were treated with FM prior to and following lesion with 6-hydroxydopamine (6-OHDA). The elevated plus-maze (EPM) and the forelimb akinesia tests were used to evaluate anxiety-like symptoms and motor impairment respectively. Blood plasma was used to measure corticosterone concentration, and striatal tissue was collected for dopamine (DA) and serotonin (5-HT) analysis. Our results show that animals exposed to early life stress displayed increased anxiety-like symptoms and elevated basal plasma corticosterone concentration which were attenuated by treatment with FM. A 6-OHDA lesion effect was evidenced by impairment in the forelimb akinesia test as well as decreased DA and 5-HT concentrations in the lesioned striatum. These effects were attenuated on DA neurons by FM treatment in the pre-lesion treated as opposed to the post-lesion treated rats. This study suggests that early treatment of anxiety-like behavior decreases the vulnerability of DA neurons to neurotoxic insults later in life thus slowing down DA degeneration in PD.

show abstract

“…Electro-convulsive therapy, Psychotherapies and Cognitive behavior therapy are particularly effective for the most severe and resistant depressions 1 . Fluvoxamine is one of the antidepressants commonly used as first line treatment for major depressive disorders 2,3 SSRIs (selective serotonin reuptake inhibitor) are antidepressant drugs that increase serotoninergic neurotransmission via the selective inhibition of neuronal reuptake of serotonin 4,5 . Fluvoxamine is BCS class II drug which having low solubility and high permeability but it is practically soluble in ethanol, so it is suitable for formulating nanosuspension.…”

Section: Introductionmentioning

confidence: 99%